Amgen vs Dell: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Dell was founded in 1984 by Michael S. Dell and is led by Michael S. Dell.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Dell
Michael S. Dell
Dell Technologies possesses one of the most famous, foundational founding stories in the history of the personal computer revolution, rooted in an aggressive, direct-to-consumer arbitrage strategy executed entirely from a college dorm room.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Dell
- Michael S. Dell1984–present
Founder, Chairman, and Chief Executive Officer
Michael Dell's bold, aggressive strategic maneuvers transformed the company from a successful consumer PC manufacturer into a global leader in complex enterprise data center infrastructure and advanced cloud computing.
Source - Kevin Rollins2004–2007
President and Chief Executive Officer
As CEO from 2004 to 2007, he oversaw a period of severe stagnation, losing the company's #1 PC market share position to HP, forcing Michael Dell to return and retake control.
Source - Jeff Clarke2017–present
Vice Chairman and Chief Operating Officer
As Vice Chairman and Co-COO, he is the primary operational architect of Dell's Infrastructure Solutions Group, transforming the company from a PC maker into a massive enterprise IT vendor.
Source - David Kennedy2025–present
Chief Financial Officer
As Chief Legal Officer, he navigated the highly contentious 2013 leveraged buyout that took the company private, and the equally complex 2018 transaction that returned it to the public markets.
Source
Timeline: Amgen and Dell side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1984Dell
PC's Limited Founded
Michael Dell starts PC's Limited from his University of Texas dorm room using a direct-sales PC model.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1988Dell
Dell Goes Public
Dell Computer Corporation completes its initial public offering and scales internationally.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2001Dell
Dell Becomes Largest PC Maker
Dell becomes the world's largest PC maker by market share, validating the direct model at global scale.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2007Dell
Michael Dell Returns as CEO
Michael Dell returned as chief executive in January 2007, replacing Kevin Rollins.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2013Dell
Dell Goes Private
Michael Dell and Silver Lake take Dell private in a leveraged buyout to reposition the company away from public-market pressure.
2016Dell
EMC Acquired
Dell completes the EMC acquisition, creating Dell Technologies and expanding into enterprise storage, infrastructure, and VMware-linked assets.
2018Dell
Dell Returns to Public Markets
Dell Technologies returns to public-market trading through a complex transaction involving its VMware tracking stock.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021Dell
VMware Spin-Off
Dell completes the VMware spin-off, simplifying the corporate structure and reducing debt.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Dell
PC Brands Simplified
Dell introduces simplified Dell, Dell Pro and Dell Pro Max PC brand tiers at CES 2025.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Dell
Record $113.5B Fiscal Year
Dell reports record fiscal 2026 revenue of $113.5B, $64.1B of AI server orders and a $43B AI backlog.
2026Dell
$95B AI Server Backlog
Q2 fiscal 2027 revenue rises 58% to $47.0B; AI orders hit $60.9B and backlog reaches $95B; full-year guidance raised to about $192B.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Dell
- EMC Corporation2016$67B
- Quest Software2012$2.4B
- Perot Systems2009$3.9B
- Alienware2006Undisclosed
Questions about Amgen vs Dell
Who is the CEO of Amgen Inc. and Dell Technologies Inc.?
Amgen Inc. is led by Robert A. Bradway and Dell Technologies Inc. is led by Michael S. Dell. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Dell Technologies Inc.?
Amgen Inc. was founded in 1980 — 4 years before Dell Technologies Inc., which was founded in 1984. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Dell Technologies Inc..
How many employees does Amgen Inc. have compared to Dell Technologies Inc.?
Amgen Inc. employs approximately 31,500 people, while Dell Technologies Inc. employs approximately 97,000. Dell Technologies Inc. has the larger workforce at 97,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Dell Technologies Inc. headquartered?
Both Amgen Inc. and Dell Technologies Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Dell Technologies Inc.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Dell Technologies Inc. was founded by Michael S. Dell.
Which company has a longer operating history — Amgen Inc. or Dell Technologies Inc.?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. Dell Technologies Inc. has been in operation for around 42 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Dell overview